Facebook
Twitter
LinkedIn
Forward
Highlights of the 21st Annual South Beach Symposium 2023
The ever-increasing impact of dermatologic conditions continues to be a major challenge for dermatologists and other health care providers in the United States (US). Dermatology practitioners diagnose and treat more than 3000 diseases across the age spectrum. Therefore, clinicians are challenged to remain current in their knowledge and competence in the diagnosis and management of cutaneous disease.
The 21st Annual South Beach Symposium, which took place in Miami Beach, FL, on February 9-12, 2023, addressed many of these gaps and more in an effort to provide evidence-based, practical education for dermatologists and dermatologic practitioners. This activity comprises the most valuable highlights of the educational content presented by nationally recognized dermatology experts, and spanning several disease states in dermatology, including atopic dermatitis, psoriasis, acne, rosacea, and actinic keratoses. This content is available to practitioners who were unable to join us in person to stay up to date on the most prevalent dermatological conditions and their newest treatments.
Target Audience
This activity is designed for an audience of physicians, nurses, pharmacists, and other allied health providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology.
Learning Objectives
- Discuss new and emerging therapies for the treatment of acne
- Review the safety and efficacy of new and emerging targeted therapies for treatment of atopic dermatitis
- Review clinical safety and efficacy data for new and emerging agents for treatment of psoriasis
- Summarize expert recommendations for management of actinic keratoses
Aesthetic Lasers for Med Derm Issues - Michael Gold, MD (15 mins)
What's New in Topicals for Acne and Rosacea? - Hilary Baldwin, MD (15 mins)
What's New for Psoriasis? - Leon Kircik, MD (15 mins)
Boxed Warning Toolkit: Myths vs Science - Christopher Bunick, MD, PhD (15 mins)
JAK Mechanisms Update: Oral, Topical and Everything in Between - Brett King, MD, PhD (20 mins)
New Approvals in Biologics for AD - Karan Lal, DO (10 mins)
The Great Debate: Psoriasis - Leon Kircik, MD, and Andrew Alexis, MD (15 mins)
Best Practices in Managing AK - Todd Schlesinger, MD (15 mins)
Andrew F. Alexis, MD, MPH
Vice Chair for Diversity and Inclusion
Weill Cornell Medicine
New York, NY
Hilary E. Baldwin, MD
Medical Director
The Acne Treatment and Research Center
New York, NY
Christopher G. Bunick, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, CT
Michael H. Gold, MD
Medical Director, Owner
Gold Skin Care Center, Tennessee Clinical Research Center
Nashville, TN
Brett A. King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, CT
Leon H. Kircik, MD
Medical Director Physicians Skin Care, PLLC
KYSkin Sciences, PLLC
DermResearch, PLLC
Louisville, KY
Karan Lal, DO, MS
Director of Pediatric and Cosmetic Dermatology
Affiliated Dermatology
Phoenix, AZ
Todd E. Schlesinger, MD
Director
Dermatology and Laser Center of Charleston
Charleston, SC
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse
2 ANCC contact hour
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid until May 15, 2024. PAs should only claim credit commensurate with the extent of their participation.
Commercial Support
This activity is supported by an educational grant from Almirall.
| Disclosures | ||
|---|---|---|
| Name | Relationship | Company |
Andrew Alexis, MD, MPH | Advisor | Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L’Oreal, BMS, Bausch health, UCB, Vyne , Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel , Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara, EPI, ASLAN |
| Consultant | Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L’Oreal, BMS, Bausch health, UCB, Vyne , Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel , Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara, EPI, ASLAN |
| Researcher | Leo, Novartis, Almirall, Bristol-Myers-Squibb, Amgen, Vyne, Galderma, Valeant (Bausch Health), Cara, Arcutis, Dermavant, Abbvie, Castle |
| Royalties or patent beneficiary | Springer, Wiley-Blackwell, Wolters Kluwer Health |
| Speaker | Regeneron, SANOFI-Genzyme, Pfizer, BMS |
Hilary Baldwin, MD | Advisor, Consultant, Speaker | Galderma, Bausch, Sun, Journey, EPI, Almirall, Cutera |
| Christopher Bunick, MD, PhD | Consultant | Arcutis, Abbvie, Almirall, LEO Pharma, UCB, Pfizer, Sanofi-Regeneron, Novartis |
Researcher | Almirall | |
Speaker | LEO-Pharma, UCB | |
| Michael Gold, MD | Consultant | Acclaro, Aerolase, Aesthetic Management Partners, Aesthetic Bio Medical, Alastin, Allergan, Almirall, Bausch Health, BioFrontera, BrandMD, Croma, Dermaroller, Endo Aesthetics, EndyMed, Galderma, Hugel, InMode, IntraDerm, Leo Pharma, Lumenis, Merz, Mindera, MTF, NanoPass, Neauvia, Nutrafol, Pierre Fabre / Glytone, Prescriber's Choice, Revance, Revision, Roher Aesthetic, Sciton, Sensus, Senté, Skinbetter Science, SkinCeuticals, Skin Medica, Sofwave, Stratpharma, Suneva, Topix, Venus Concept |
Speaker | Speaker: Acclaro, Aerolase, Aesthetic Management Partners, Aesthetic Bio Medical, Alastin, Allergan, Almirall, Bausch Health, BioFrontera, BrandMD, Croma, Dermaroller, Endo Aesthetics, EndyMed, Galderma, Hugel, InMode, IntraDerm, Leo Pharma, Lumenis, Merz, Mindera, MTF, NanoPass, Neauvia, Nutrafol, Pierre Fabre / Glytone, Prescriber's Choice, Revance, Revision, Roher Aesthetic, Sciton, Sensus, Senté, Skinbetter Science, SkinCeuticals, Skin Medica, Sofwave, Stratpharma, Suneva, Topix, Venus Concept, | |
| Brett King, MD, PhD | Advisor | Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio |
Consultant | Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio | |
Individual Stocks and stock options | BiologicsMD | |
| Leon Kircik, MD | Consultant | Abbott, Acambis, Aclaris, Allergan, Almirall, Amgen, Anacor, Astellas, Asubio, Berlex, Biogen-Idec, Biolife, Biopelle, Boehringer-Ingleheim, Breckenridge Pharma, Cellceutix, Celgene, Centocor, Cipher, Coherus, Colbar, Collagenex, Combinatrix, Connetics, Coria, Dermavant, Dermik, Dermira, Dow, Dusa Pharmaceuticals, Eli Lilly, Exeltis, EOS, Ferndale, Galderma, Genentech, Glaxo-Smith Kline, HealthPoint, Idera, Intendis, Innovail, Isdin, Johnson & Johnson, 3M, Leo, L'Oreal, Maruho, Medicis, Merck, Merz, NanoBio, Novartis, Novan, Nucryst, Obagi, Onset Therapeutics, OrthoNeutrogena, PediaPharma, Pfizer, PharmaDerm, Promius, Puracap, QLT, Quatrix, Quinnova, Serono, SkinMedica, Stiefel, Sun Pharma, Taro, TolerRx, Triax Pharmaceuticals, UCB, Valeant, Warner & Chilcott, Xenoport, ZAGE |
Speaker | Abbott, Acambis, Aclaris, Allergan, Almirall, Amgen, Anacor, Astellas, Asubio, Berlex, Biogen-Idec, Biolife, Biopelle, Boehringer-Ingleheim, Breckenridge Pharma, Cellceutix, Celgene, Centocor, Cipher, Coherus, Colbar, Collagenex, Combinatrix, Connetics, Coria, Dermavant, Dermik, Dermira, Dow, Dusa Pharmaceuticals, Eli Lilly, Exeltis, EOS, Ferndale, Galderma, Genentech, Glaxo-Smith Kline, HealthPoint, Idera, Intendis, Innovail, Isdin, Johnson & Johnson, 3M, Leo, L'Oreal, Maruho, Medicis, Merck, Merz, NanoBio, Novartis, Novan, Nucryst, Obagi, Onset Therapeutics, OrthoNeutrogena, PediaPharma, Pfizer, PharmaDerm, Promius, Puracap, QLT, Quatrix, Quinnova, Serono, SkinMedica, Stiefel, Sun Pharma, Taro, TolerRx, Triax Pharmaceuticals, UCB, Valeant, Warner & Chilcott, Xenoport, ZAGE | |
Karan Lal, DO | Speaker | Incyte |
| Todd Schlesinger, MD | Advisor | Regeneron, Genentech, Sun Pharma, Biofrontera |
Consultant | Almirall, Biofrontera, Galderma, Regeneron | |
Independent Contractor | Almirall, Biofrontera, Galderma, Regeneron | |
Researcher | Almirall, Biofrontera, Galderma, Regeneron | |
Speaker | Speakers' Bureau - Incyte, L'Oreal, Lilly, Ortho Dermatologics | |
Dorothy Caputo, MA, BSN, RN, Senior Director of Continuing Education & Compliance | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
| All of the relevant financial relationships listed for these individuals have been mitigated | ||
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy)
Available Credit
- 2.00 AAPA Category I CME
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC
- 2.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.